Insights into direct nose to brain delivery: Current status and future perspective

Drug Delivery

Volumn 21, Issue 2, 2014, Pages 75-86

  Mittal, Deepti ^a   Ali, Asgar ^a   Md, Shadab ^a   Baboota, Sanjula ^a   Sahni, Jasjeet K ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Blood brain barrier; Brain targeting; Intranasal delivery; Nanoparticles; Olfactory pathway

Indexed keywords

BETA INTERFERON; BROMOCRIPTINE; BUSPIRONE; CENTRAL NERVOUS SYSTEM AGENTS; CLONAZEPAM; DEFEROXAMINE; DIDANOSINE; DULOXETINE; ERYTHROPOIETIN; ESTRADIOL; HEXARELIN; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SUMATRIPTAN; VENLAFAXINE; ZOLMITRIPTAN;

ALZHEIMER DISEASE; BRAIN; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG DELIVERY SYSTEM; HUMAN; MIGRAINE; NONHUMAN; NOSE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; NOSE; OLFACTORY MUCOSA;

EID: 84896899453     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.838713     Document Type: Review

References (71)

1. Alam MI, Baboota S, Ahuja A, et al. (2012). Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res 46: 1133-8.
2. Alam MI, Baboota S, Ahuja A, et al. (2011). Nanostructured lipid carrier containing CNS acting drug: formulation, optimization and evaluation. Curr Nanosci 7:1014-27.
3. Al-Ghananeem AM, Saeed H, Florence R, et al. (2010). Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J Drug Target 18:381-8.
4. Anderson BD, Morgan ME, Singhal D. (1995). Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm Res 12:1126-33.
5. Anderson DW, Ellenberg JH, Leventhal CM, et al. (1992). Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31:333-6.
6. Balo R. (1994). Buspirone in the treatment of separation anxiety in an adolescent boy. J Clin Psychopharmacol 14:360-1.
7. Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. (2003). The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 61:313-20.
8. Brines ML, Ghezzi P, Keenan S, et al. (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-31.
9. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol 25:871-80.
10. Chakraborty C, Sarkar B, Hsu CH, et al. (2009). Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol 93: 285-6.
11. Cho K, Wang X, Nie S, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310-16.
12. Critchley H, Davis SS, Farraj NF. (1994). Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol 46:651-6.
13. Degim IT, Acarturk F, Erdogan D, Lortlar ND. (2003). Transdermal administration of bromocriptine. Biol Pharm Bull 26:501-5.
14. Denora N, Trapani A, Laquintana V, et al. (2009). Recent advances in medicinal chemistry and pharmaceutical technology strategies for drug delivery to the brain. Curr Top Med Chem 9:182-96.
15. Dhanda DS, Frey WH II, Leopold D, Kompella UB. (2005). Approaches for drug deposition in the human olfactory epithelium. Drug Del Tech 5:64-72.
16. Dhuria SV, Hanson LR, Frey WH. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:1654-73.
17. Dodane V, Amin Khan M, Merwin JR. (1999). Effect of chitosan on epithelial permeability and structure. Int J Pharm 182:21-32.
18. Dragsten PR, Hallaway PE, Hanson GJ, et al. (2000). First human studies with a high-molecular-weight iron chelator. J Lab Clin Med 135: 57-65.
19. Ehrenreich H, Timner W, Siren AL. (2004). A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apher Sci 31:39-44.
20. Esposito E, Mariani P, Laura Ravani L, et al. (2012). Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm 80:306-14.
21. Fazil M, Shadab M, Haque S, et al. (2012). Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6-15.
22. Freret T, Valable S, Chazalviel L, et al. (2006). Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci 23:1757-65.
23. Galichet LY. (2004). Clarke's Analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. London, UK: Pharmaceutical Press. 2:726-7.
24. Ghigo E, Arvat E, Gianotti L, et al. (1994). Growth hormone-releasing activity of hexarelin, a newsynthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 78:693-8.
25. Goadsby PJ, Yates R. (2006). Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache 46:138-49.
26. Hanson LR, Roeytenberg A, Martinez PM, et al. (2009). Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J pharmacol Exp Ther 330:679-86.
27. Haque S, Shadab M, Fazil M, et al. (2012). Venlafaxine loaded chitosan NPs for brain targeting, Pharmacokinetic and pharmacodynamic evaluation. Carbo Polym 89:72-9.
28. Hartman NR, Yarchoan R, Pluda JM, et al. (1990). Pharmacokinetics of 20,30-dideoxyadenosine and 20,30-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 47:647-54.
29. Jadhav KR, Gambhire MN, Shaikh IM. (2007). Nasal drug delivery system-Factors affecting and application. Curr Drug Ther 2:27-38.
30. Jain A, Jain SK. (2011). Drug targeting to the brain-a review. Curr Nanosci 7:21-36.
31. Jain R, Nabar S, Dandekar P, Patravale V. (2010a). Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 27:655-64.
32. Jain R, Nabar S, Dandekar P, et al. (2010b). Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond) 5:575-87.
33. Jenner P, Pratt JA, Marsden CD. (1986). Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol 43:629-43.
34. Khan S, Patil K, Bobade N, et al. (2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 18: 223-34.
35. Khan S, Patil K, Yeole P, Gaikwad R. (2009). Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J Pharm Pharmacol 61:669-75.
36. Korbonits M, Little JA, Forsling ML, et al. (1999). The effect of growth hormone secretagogues and neuropeptide Yon hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 11: 521-8.
37. Kosasa T, Kuriya Y, Matsui K, Yarnanishi Y. (1999). Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rat. Eur J Pharmacol 386: 7-13.
38. Kumar M, Misra A, Babbar AK, et al. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358:285-91.
39. Letchford K, Burt H. (2007). A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259-69.
40. Lim JH, Kim SS, Boo DH, et al. (2009). Protective effect of bromocriptine against BH4-induced Cath. A cell death involving up-regulation of antioxidant enzymes. Neurosci Lett 451:185-9.
41. Maiese K, Li F, Chong ZZ. (2004). Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 25:577-83.
42. Md S, Khan RA, Mustafa G, et al. (2012). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 48:393-405.
43. Muchow M, Maincent P, Muller RH. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 34:1394-405.
44. Mustafa G, Baboota S, Ali J, Ahuja A. (2012). Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of Parkinson: an in vitro-ex vivo evaluation. Curr Nanosci 29:293-300.
45. Patel S, Chavhan S, Soni H, et al. (2011). Brain targeting of risperidoneloaded solid lipid nanoparticles by intranasal route. J Drug Target 19: 468-74.
46. Perry CM, Markham A. (1998). Sumatriptan: an updated review of its use in migraine. Drugs 55:889-922.
47. Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal drug delivery: how, why and what for. J Pharm Pharm Sci 12:288-311.
48. Platanias LC, Fish EN. (1999). Signaling pathways activated by interferons. Exp Hematol 27:1583-92.
49. Putheti R, Patil MC, Obire O. (2009). Nasal drug delivery in pharmaceutical and biotechnology: present and future. J Sci Tec 4:1-21.
50. Ray B, Lahiri DK. (2009). Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 9:434-44.
51. Redzic Z. (2011). Molecular biology of the blood-brain and the bloodcerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8:1-23.
52. Rey E, Treluer JM, Pons G. (1999). Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet 36:409-24.
53. Rossa TM, Martineza PM, Rennera JC, et al. (2004). Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple sclerosis. J Neuroimmunol 151:66-77.
54. Schupf N, Winsten S, Patel B, et al. (2006). Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett 406:298-302.
55. Stahl SM, Grady MM, Moret C, Briley M. (2005). SNRIs: their pharmacology clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732-47.
56. Tfelt-Hansen P, De Vries P, Saxena PR. (2000). Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-87.
57. Torchilin VP. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24:1-16.
58. Vautier S, Lacomblez L, Chacun H, et al. (2006). Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci 27:167-74.
59. Vyas TK, Babbar AK, Sharma RK, Misra A. (2005). Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target 13:317-24.
60. Vyas TK, Babbar AK, Sharma RK, et al. (2006a). Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J Pharm Sci 95:570-80.
61. Vyas TK, Babbar AK, Sharma RK, et al. (2006b). Preliminary braintargeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm Sci Tech 7:E49-57.
62. Wang F, Jiang X, Lu W. (2003). Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 263:1-7.
63. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 70:735-40.
64. Wilson AD, Howell C, Waring WS. (2007). Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci 32:97-101.
65. Wilson B, Samanta MK, Santhi K, et al. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 1200:159-68.
66. Wong HL, Wu XY, Bendayan R. (2012). Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64: 686-700.
67. Yang S, Zhu J, Lu Y, et al. (1999). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16: 751-7.
68. Ying W. (2008). The nose may help the brain: intranasal drug delivery for treating neurological diseases. Future Neurol 3:1-4.
69. Yu H, Kim K. (2009). Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, Hexarelin after intranasal administration to rabbits. Int J Pharm 378:73-9.
70. Yu YP, Xu Q, Zhang Q, et al. (2005). Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 387:5-10.
71. Zhang Q, Jiang X, Jiang W, et al. (2004). Preparation of nimodipine loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int J Pharm 275:85-96.